Adaptive immunity programs in breast cancer Adaptive immunity in breast cancer

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/imm.12664 This article is protected by copyright. All rights reserved. Received Date : 20-Jun-2016 Revised Date : 12-Aug-2016 Accepted Date : 22-Aug-2016 Article type : Review

[1]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[2]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. Marmé,et al.  Immunotherapy in Breast Cancer , 2016, Oncology Research and Treatment.

[4]  Chao Cheng,et al.  Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles , 2016, Nature Communications.

[5]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[6]  M. Postow,et al.  Immune checkpoint modulation: rational design of combination strategies. , 2015, Pharmacology & therapeutics.

[7]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[8]  Chao Cheng,et al.  Integrative analysis of survival-associated gene sets in breast cancer , 2015, BMC Medical Genomics.

[9]  C. Sentman,et al.  Bispecific T‐cell engagers for cancer immunotherapy , 2015, Immunology and cell biology.

[10]  A. Thakur,et al.  Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial , 2015, Clinical Cancer Research.

[11]  E. Mittendorf,et al.  Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer , 2015, BioDrugs.

[12]  M. Aglietta,et al.  Recent advances in the development of breast cancer vaccines , 2014, Breast cancer.

[13]  D. Rimm,et al.  Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Clinical Cancer Research.

[14]  L. Zitvogel,et al.  Trial watch: IDO inhibitors in cancer therapy , 2014, Oncoimmunology.

[15]  Kathleen A Cronin,et al.  US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.

[16]  Scott D. Brown,et al.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.

[17]  P. Darcy,et al.  Clinical application of genetically modified T cells in cancer therapy , 2014, Clinical & translational immunology.

[18]  F. Schuetz,et al.  Adoptive immunotherapy of metastatic breast cancer: present and future , 2014, Cancer and Metastasis Reviews.

[19]  L. Coussens,et al.  Dendritic Cells, Inflammation, and Breast Cancer , 2013, Cancer journal.

[20]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[21]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[22]  Benjamin Haibe-Kains,et al.  CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.

[23]  A. Schneeweiss,et al.  Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial , 2013, Cancer Immunology, Immunotherapy.

[24]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Criscitiello.  Tumor-Associated Antigens in Breast Cancer , 2012, Breast Care.

[26]  Stefan Michiels,et al.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  I. Ellis,et al.  The prognostic significance of B lymphocytes in invasive carcinoma of the breast , 2012, Breast Cancer Research and Treatment.

[28]  S. Leung,et al.  CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer , 2012, Breast Cancer Research.

[29]  Michael J. Bevan,et al.  CD8+ T Cells: Foot Soldiers of the Immune System , 2011, Immunity.

[30]  D. Yin,et al.  CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.

[31]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Wei Zheng,et al.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. , 2011, The Lancet. Oncology.

[33]  C. Aspord,et al.  Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation , 2011, The Journal of experimental medicine.

[34]  L. Sherman,et al.  CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.

[35]  Yuan Qi,et al.  Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Watanabe,et al.  Regulatory T cells and breast cancer: implications for immunopathogenesis , 2010, Cancer and Metastasis Reviews.

[37]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[38]  C. Caldas,et al.  Triple negative breast cancers: clinical and prognostic implications. , 2009, European journal of cancer.

[39]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[40]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[41]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[42]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[43]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[44]  S. Dermime,et al.  FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy , 2008, BMC Cancer.

[45]  J. A. Lopez,et al.  Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer , 2007, British Journal of Cancer.

[46]  M. Bregni,et al.  Current role of allogeneic stem cell transplantation in breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[48]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[49]  Alexander H Enk,et al.  Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. , 2007, Journal of dermatological science.

[50]  C. Aspord,et al.  Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development , 2007, The Journal of experimental medicine.

[51]  K. Tanabe,et al.  Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.

[52]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[54]  C. Schmidt,et al.  The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction , 2006, Breast Cancer Research.

[55]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[56]  M. Sheaff,et al.  The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. , 2003, Surgery.

[57]  A. Vincent-Salomon,et al.  Tumor Antigens and Antigen-Presenting Capacity in Breast Cancer , 2003, Pathobiology.

[58]  D. Hart,et al.  Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression , 2002, British Journal of Cancer.

[59]  L. Harris,et al.  First-Line Herceptin® Monotherapy in Metastatic Breast Cancer , 2001, Oncology.

[60]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[61]  D. Jäger,et al.  Challenges to the development of antigen-specific breast cancer vaccines , 2001, Breast Cancer Research.

[62]  G. Heppner,et al.  Immunological enhancement of breast cancer , 1997, Parasitology.

[63]  D. Carbone,et al.  Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[64]  M. Papamichail,et al.  Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer , 1994, Cancer.

[65]  J. Hurlimann,et al.  Mononuclear cells infiltrating human mammary carcinomas: Immunohistochemical analysis with monoclonal antibodies , 1985, International journal of cancer.

[66]  P. Beverley,et al.  Characterisation of breast cancer infiltrates using monoclonal antibodies to human leucocyte antigens. , 1984, British Journal of Cancer.

[67]  C. Desmarais,et al.  Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. , 1983, Journal of the National Cancer Institute.

[68]  H. Soliman.  Immunotherapy strategies in the treatment of breast cancer. , 2013, Cancer control : journal of the Moffitt Cancer Center.

[69]  B. Chauffert,et al.  Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy , 2010, Breast Cancer Research and Treatment.

[70]  F. Quismorio,et al.  Circulating anti-tumor and autoantibodies in breast carcinoma: Relationship to stage and prognosis , 2005, Breast Cancer Research and Treatment.

[71]  S. Pillai,et al.  Innate immunity. , 1996, Current opinion in immunology.